Arrowhead Research Corp (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that additional clinical data on ARC-520, its RNAi therapeutic candidate for the treatment of chronic hepatitis B infection, will be presented in the late-breaking poster session at The Liver Meeting® 2015, the 66th Annual Meeting of the American Association for the Study of Liver Disease (AASLD) being held on November 13-17, 2015, in San Francisco.
The late-breaking abstract details results from the Heparc-2001, Phase 2 study of ARC-520 in combination with entecavir (ETV). Key findings include the following:
- Naïve patients reduced viral DNA up to 4.3 log (mean 2.2 log)
- Naïve e-antigen (HBeAg) positive patients reduced surface antigen (HBsAg) up to 1.9 log (mean max 1.1 log)
- ARC-520 reduced HBeAg up to 1.7 log (mean max 1.2 log)
- ARC-520 therapy was well tolerated with no adverse events rated serious, severe, drug-related or causing withdrawal from the trial
- 15 patients are continuing in follow-up and additional results may be available to report at The Liver Meeting
Christopher Anzalone, Ph.D., president and CEO of Arrowhead, said, “In the Phase 2 study, ARC-520 effectively inhibited cccDNA-derived mRNA with protein knockdown up to 99% or 1.9 logs observed. This is the highest knockdown ever reported using RNAi in humans. Our clinical program and our study in chronically infected chimps continue to teach us a lot about HBV and we are thrilled to get the opportunity to make three presentations at The Liver Meeting next month.”
With the addition of the late-breaking poster, Arrowhead has the following three abstracts accepted for presentation at the Liver Meeting:
November 15, 3:15 p.m. PST – Christine Wooddell, Ph.D., group leader will deliver an oral presentation titled, “Reductions in cccDNA under NUC and ARC-520 therapy in chimpanzees with chronic hepatitis B virus infection implicate integrated DNA in maintaining circulating HBsAg”
November 16, 8:00 a.m. – 5:30 p.m. PST – Man-Fung Yuen, M.D., Ph.D., chair of gastroenterology and hepatology, The University of Hong Kong, and deputy chief of service,Queen Mary Hospital department of medicine, Hong Kong, will deliver a late-breaking poster presentation titled, “ARC-520 produces deep and durable knockdown of viral antigens and DNA in a phase II study in patients with chronic hepatitis B”
November 17, 8:00 a.m. – 12:00 p.m. PST – Christine Wooddell, Ph.D., group leader will deliver a poster presentation titled, “Monthly dosing of ARC-520 in chronically hepatitis B virus infected chimpanzees produces rapid, deep and durable reductions in circulating viral antigens” (Original Source)
Shares of Arrowhead Research Corp. opened today at $5.18 and are currently trading up at $5.24. ARWR has a 1-year high of $9.36 and a 1-year low of $4.35. The stock’s 50-day moving average is $6.12 and its 200-day moving average is $6.47.
On the ratings front, Arrowhead Research has been the subject of a number of recent research reports. In a report issued on September 25, Piper Jaffray analyst Edward Tenthoff reiterated a Buy rating on ARWR, with a price target of $20, which represents a potential upside of 286.1% from where the stock is currently trading. Separately, on August 5, RBC’s Michael Yee maintained a Hold rating on the stock and has a price target of $9.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Edward Tenthoff and Michael Yee have a total average return of 8.3% and 3.6% respectively. Tenthoff has a success rate of 40.8% and is ranked #751 out of 3793 analysts, while Yee has a success rate of 56.7% and is ranked #945.
Arrowhead Research Corp is engaged in developing novel drugs to treat intractable diseases by silencing the genes. The Company’s drug candidate ARC-520 is designed to treat chronic hepatitis B infection.